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Hopefully, these counteractions will alleviate the low cov-
erage of hepatitis B vaccine in the country.
In the real world, there is no perfect means for a given
treatment or prevention that bears no risk. In hepatitis
B, any presumed risk of untoward events possibly asso-
ciated with hepatitis B immunoprophylaxis should be
weighed against the disease burden caused by the hepa-
titis B virus. Education of the public and health profes-
sionals is essential [10], and it should include everyone in
the chain of releasing the information, right from the
sources all the way down to academia and the public.
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On the role of platelets in the pathogenesis of viral hepatitis
To the Editor:
We read with interest the commentary by Ulrich
Spengler [1] where he evaluated a recent manuscript
by Lang et al. [2] on the role of platelet-derived seroto-
nin in the pathogenesis of viral hepatitis. We were
somewhat surprised to see that work constituting the
foundation of the above-mentioned study was not ci-
ted. A few years ago our group started investigating
the role of platelets in the pathogenesis of viral hepati-
tis, using diﬀerent mouse models that include trans-
genic mice replicating hepatitis B virus (HBV) at high
levels in the hepatocyte and mice infected with hepato-
tropic adenoviruses and arenaviruses (i.e. lymphocytic
choriomeningitis virus [LCMV]). Similar to humans in-
fected with HBV or hepatitis C virus (HCV), liver dis-
ease in these models is mostly a consequence of the
virus-speciﬁc CD8 T cell response aimed at viral clear-
ance. We found that platelets play a previously unrec-
ognized role in viral hepatitis. Upon activation,
platelets contribute to liver disease and viral clearance
by promoting the recruitment of virus-speciﬁc cytotoxic
T lymphocytes (CTL) into the liver [3]. Further exper-
iments suggested that this eﬀect depends on speciﬁc
interactions between platelets and CTL likely occurring
within the hepatic microcirculation and helping CTL to
extravasate, reach target cells and perform pathogenic
and antiviral eﬀector functions [4–6]. We conﬁrmed
these results in follow-up studies by showing reduction
of hepatic CTL recruitment after pharmacological inhi-
bition of platelet activation [7]. The paper by Lang
et al. nicely reiterates a role for platelets in the patho-
genesis of liver disease and provides a novel mechanis-
tic hint. They identiﬁed serotonin as a potential
molecular mediator of CTL recruitment and liver dam-
age in LCMV-infected mice. Although the use of
LCMV as a model for human HBV and HCV infection
must be taken cautiously (unlike HBV and HCV that
infect hepatocytes almost exclusively, LCMV infects
primarily non-parenchymal cells of the liver such as
Kupﬀer cells [8]), the study by Lang et al. raises impor-
tant questions. Where does serotonin come from dur-
ing liver inﬂammation? Is it platelet-derived as the
authors seem to suggest? What cells respond to seroto-
nin? What serotonin receptors are involved? The
answers to these questions are important if we envisage
future manipulations of serotonin-dependent pathways
600 Letters to the Editor / Journal of Hepatology 51 (2009) 593–600designed to either counteract excessive liver damage or,
conversely, promote the hepatic homing and antiviral
potential of CTL induced by therapeutic vaccines. In
addition to serotonin, it is likely that other platelet-de-
rived molecular mediators of liver damage will be dis-
covered in the years to come, allowing us to better
understand the complex interplay between platelets
and CTL in the inﬂamed liver microenvironment.
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